Lynozyfic: A New Hope in Blood Cancer Treatment
What Is Lynozyfic? Lynozyfic is a bispecific antibody therapy, meaning it simultaneously binds to two different targets. It attaches to BCMA (B-cell maturation antigen), a protein found on the surface of multiple myeloma cells, and CD3, a molecule found on T cells—critical components of the immune system. This dual binding draws T cells directly to cancerous plasma cells, enabling them to destroy the malignant cells more effectively. This approach not only targets the disease more precisely but also limits damage to healthy tissue, a significant concern in traditional chemotherapy.
